Literature DB >> 17078173

Ranibizumab.

Raja Narayanan, Baruch D Kuppermann, Carole Jones, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17078173     DOI： 10.1038/nrd2157

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  10 in total

1.  Extending foldamer design beyond α-helix mimicry: α/β-peptide inhibitors of vascular endothelial growth factor signaling.

Authors:  Holly S Haase; Kimberly J Peterson-Kaufman; Sheeny K Lan Levengood; James W Checco; William L Murphy; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2012-05-01       Impact factor: 15.419

2.  Aflibercept.

Authors:  Michael W Stewart; Seden Grippon; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

3.  Digital-to-biological converter for on-demand production of biologics.

Authors:  Kent S Boles; Krishna Kannan; John Gill; Martina Felderman; Heather Gouvis; Bolyn Hubby; Kurt I Kamrud; J Craig Venter; Daniel G Gibson
Journal:  Nat Biotechnol       Date:  2017-05-29       Impact factor: 54.908

Review 4.  Clinical pharmacology of intravitreal anti-VEGF drugs.

Authors:  Stefano Fogli; Marzia Del Re; Eleonora Rofi; Chiara Posarelli; Michele Figus; Romano Danesi
Journal:  Eye (Lond)       Date:  2018-02-05       Impact factor: 3.775

5.  Broad spectrum antiangiogenic treatment for ocular neovascular diseases.

Authors:  Ofra Benny; Kei Nakai; Takeru Yoshimura; Lauren Bazinet; James D Akula; Shintaro Nakao; Ali Hafezi-Moghadam; Dipak Panigrahy; Pouya Pakneshan; Robert J D'Amato
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

6.  A fluorescence polarization assay for identifying ligands that bind to vascular endothelial growth factor.

Authors:  Kimberly J Peterson; Jack D Sadowsky; Elizabeth A Scheef; Soumen Pal; Katerina D Kourentzi; Richard C Willson; Emery H Bresnick; Nader Sheibani; Samuel H Gellman
Journal:  Anal Biochem       Date:  2008-03-28       Impact factor: 3.365

7.  Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab.

Authors:  Sarath K Yandrapu; Arun K Upadhyay; J Mark Petrash; Uday B Kompella
Journal:  Mol Pharm       Date:  2013-11-12       Impact factor: 4.939

8.  Results of Ranibizumab Treatment of the Myopic Choroidal Neovascular Membrane according to the Axial Length of the Eye.

Authors:  Alexandr Stepanov; Martin Pencak; Jan Nemcansky; Veronika Matuskova; Marketa Stredova; David Beran; Jan Studnicka
Journal:  J Ophthalmol       Date:  2020-05-12       Impact factor: 1.909

Review 9.  Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.

Authors:  Md Harunur Rashid
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

Review 10.  Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology.

Authors:  María L Formica; Hamoudi G Awde Alfonso; Santiago D Palma
Journal:  Pharmacol Res Perspect       Date:  2021-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.